Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 May 29;13(11):3201.
doi: 10.3390/jcm13113201.

Effects of Hypoxia and Inflammation on Hepcidin Concentration in Non-Anaemic COVID-19 Patients

Katarina Gugo  1   2 , Leida Tandara  1   3 , Gordana Juricic  4 , Mirela Pavicic Ivelja  2   5 , Lada Rumora  6
Affiliations

Effects of Hypoxia and Inflammation on Hepcidin Concentration in Non-Anaemic COVID-19 Patients

Katarina Gugo et al. J Clin Med. .

Abstract

Background/Objectives: This study aimed to explore the influence of hypoxia, inflammation, and erythropoiesis on hepcidin and other iron status parameters in non-anaemic COVID-19 patients admitted to the emergency unit before the introduction of therapeutic interventions. Methods: Ninety-six COVID-19 patients and 47 healthy subjects were recruited. Patients were subdivided into hypoxic or normoxic groups and, after follow-up, into mild and moderate, severe or critical disease severity groups. Iron, unsaturated iron-binding capacity (UIBC), ferritin, C-reactive protein (CRP), and interleukin 6 (IL-6) were measured on automatic analysers. ELISA kits were used for hepcidin and erythropoietin (EPO) determination. We calculated total iron-binding capacity (TIBC) and ratios of hepcidin with parameters of iron metabolism (ferritin/hepcidin, hepcidin/iron), inflammation (hepcidin/CRP, hepcidin/IL-6), and erythropoietic activity (hepcidin/EPO). Results: Hepcidin, ferritin, EPO, CRP, IL-6, ferritin/hepcidin, and hepcidin/iron were increased, while UIBC, TIBC, hepcidin/CRP, and hepcidin/IL-6 were decreased in hypoxic compared to normoxic patients as well as in patients with severe or critical disease compared to those with mild and moderate COVID-19. Regarding predictive parameters of critical COVID-19 occurrence, in multivariable logistic regression analysis, a combination of EPO and ferritin/hepcidin showed very good diagnostic performances and correctly classified 88% of cases, with an AUC of 0.838 (0.749-0.906). Conclusions: The hypoxic signal in our group of patients was not strong enough to overcome the stimulating effect of inflammation on hepcidin expression. EPO and ferritin/hepcidin might help to identify on-admission COVID-19 patients at risk of developing a critical form of the disease.

Keywords: COVID-19; erythropoietin; ferritin; hepcidin; hypoxia; inflammation; interleukin 6; iron.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest. The funders had no role in the design of this study, the collection, analyses, or interpretation of data, the writing of this manuscript, or in the decision to publish the results.

Figures

Figure 1
Figure 1
Hepcidin (a), ferritin (b), EPO (c), and IL-6 (d) plasma concentrations in healthy subjects and in normoxic and hypoxic COVID-19 patients. Results are shown as the median with Q1–Q3 range. The difference between groups was tested using the Kruskal–Wallis test with post hoc analysis (Conover). Connectors on the graphs show between which groups a statistically significant difference was observed in post hoc analysis with p < 0.05. EPO, erythropoietin; IL-6, interleukin 6.
Figure 1
Figure 1
Hepcidin (a), ferritin (b), EPO (c), and IL-6 (d) plasma concentrations in healthy subjects and in normoxic and hypoxic COVID-19 patients. Results are shown as the median with Q1–Q3 range. The difference between groups was tested using the Kruskal–Wallis test with post hoc analysis (Conover). Connectors on the graphs show between which groups a statistically significant difference was observed in post hoc analysis with p < 0.05. EPO, erythropoietin; IL-6, interleukin 6.
Figure 2
Figure 2
Hepcidin (a), ferritin (b), EPO (c), and IL-6 (d) plasma concentrations in healthy subjects and in COVID-19 patients subdivided by disease severity by prospective follow-up. Results are shown as the median with Q1–Q3 range. The difference between groups was tested using the Kruskal–Wallis test with post hoc analysis (Conover). Connectors on the graphs show between which groups a statistically significant difference was observed in post hoc analysis with p < 0.05. EPO, erythropoietin; IL-6, interleukin 6.
Figure 2
Figure 2
Hepcidin (a), ferritin (b), EPO (c), and IL-6 (d) plasma concentrations in healthy subjects and in COVID-19 patients subdivided by disease severity by prospective follow-up. Results are shown as the median with Q1–Q3 range. The difference between groups was tested using the Kruskal–Wallis test with post hoc analysis (Conover). Connectors on the graphs show between which groups a statistically significant difference was observed in post hoc analysis with p < 0.05. EPO, erythropoietin; IL-6, interleukin 6.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. De Domenico I., Ward D.M., Langelier C., Vaughn M.B., Nemeth E., Sundquist W.I., Ganz T., Musci G., Kaplan J. The Molecular Mechanism of Hepcidin-Mediated Ferroportin Down-Regulation. Mol. Biol. Cell. 2007;18:2569–2578. doi: 10.1091/mbc.e07-01-0060. - DOI - PMC - PubMed
    1. Ganz T., Nemeth E. Hepcidin and Iron Homeostasis. Biochim. Biophys. Acta BBA Mol. Cell Res. 2012;1823:1434–1443. doi: 10.1016/j.bbamcr.2012.01.014. - DOI - PMC - PubMed
    1. Nemeth E., Tuttle M.S., Powelson J., Vaughn M.B., Donovan A., Ward D.M., Ganz T., Kaplan J. Hepcidin Regulates Cellular Iron Efflux by Binding to Ferroportin and Inducing Its Internalization. Science. 2004;306:2090–2093. doi: 10.1126/science.1104742. - DOI - PubMed
    1. Vogt A.-C.S., Arsiwala T., Mohsen M., Vogel M., Manolova V., Bachmann M.F. On Iron Metabolism and Its Regulation. Int. J. Mol. Sci. 2021;22:4591. doi: 10.3390/ijms22094591. - DOI - PMC - PubMed
    1. Weiss G. Iron and Immunity: A Double-Edged Sword. Eur. J. Clin. Investig. 2002;32((Suppl. S1)):70–78. doi: 10.1046/j.1365-2362.2002.0320s1070.x. - DOI - PubMed